Mayo Adhesive Probability Score Does Not Have Prognostic Ability in Locally Advanced Renal Cell Carcinoma.
body composition
kidney cancer
mayo adhesive probability
renal cell carcinoma
survival
Journal
Journal of kidney cancer and VHL
ISSN: 2203-5826
Titre abrégé: J Kidney Cancer VHL
Pays: Australia
ID NLM: 101695919
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
01
2023
accepted:
12
03
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
Nephrectomy remains standard treatment for renal cell carcinoma (RCC). The Mayo Adhesive Probability (MAP) score is predictive of adherent perinephric fat and associated surgical complexity, and is determined by assessing perinephric fat and stranding. MAP has additionally predicted progression-free survival (PFS), though primarily reported in stage T1-T2 RCC. Here, we examine MAP's ability to predict overall survival (OS) and PFS in T3-T4 RCC. From our prospectively maintained RCC database, patients that underwent radical nephrectomy (2009-2016) with available abdominal imaging (<90 days preop) and T3/T4 RCC underwent MAP scoring. Survival analyses were conducted with MAP scores as individual (0-5) and dichotomized (0-3 vs 4-5) using Kaplan-Meier method. Multivariable Cox proportional hazard regression models for PFS and OS were built with backward elimination. 141 patients were included. 134 (95%) and 7 (5%) had pT3 and pT4 disease, respectively. 46.1% of patients had an inferior vena cava thrombus. Mean MAP score was 3.22±1.52, with 75 (53%) patients having a score between 0-3 and 66 (47%) having a score of 4-5. Both male gender (p=0.006) and clear cell histology (p=0.012) were associated with increased MAP scores. On Kaplan-Meier and multivariable analysis, no significant associations were identified between MAP and PFS (HR=1.01, 95% CI 0.85-1.20, p=0.93) or OS (HR=1.01, 95% CI 0.84-1.21, p=0.917). In this cohort of patients with locally advanced RCC, high MAP scores were not predictive of worse PFS or OS.
Identifiants
pubmed: 36969300
doi: 10.15586/jkcvhl.v10i1.269
pii: JKCVHL-10-019
pmc: PMC10036918
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19-25Subventions
Organisme : NCI NIH HHS
ID : P30 CA138292
Pays : United States
Informations de copyright
Copyright: Schmeusser BN, et al.
Déclaration de conflit d'intérêts
All of the authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Eur Urol. 2014 Dec;66(6):1165-71
pubmed: 25192968
Urology. 2016 Mar;89:54-60
pubmed: 26723183
J Endourol. 2020 May;34(5):594-599
pubmed: 32164450
Eur Urol. 2020 Jun;77(6):761-763
pubmed: 31911011
J Urol. 2014 Oct;192(4):1043-9
pubmed: 24704011
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Eur Urol Oncol. 2022 Feb;5(1):113-117
pubmed: 34049847
Cancer Manag Res. 2019 Jul 04;11:6163-6173
pubmed: 31308752
World J Urol. 2018 Dec;36(12):1943-1952
pubmed: 29713755
J Immunother Precis Oncol. 2022 Nov 7;6(1):50-55
pubmed: 36751655
Front Oncol. 2021 Feb 01;10:622134
pubmed: 33598435
World J Urol. 2010 Jun;28(3):319-27
pubmed: 20364259